The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISAL 2019 | Investigating relapse after allo-SCT in AML
The cause of relapse in acute myeloid leukemia (AML) following allogeneic stem cell transplant is unknown, with many theories under investigation. John DiPersio, MD, PhD, of Washington University School of Medicine, Washington, WA, discusses our current understanding of this event from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany, with a major focus on CT2A.
